X

Download Cervical Cancer Introduction PowerPoint Presentation

SlidesFinder-Advertising-Design.jpg

Login   OR  Register
X


Iframe embed code :



Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / Cervical Cancer Introduction PowerPoint Presentation

Cervical Cancer Introduction PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

PowerPoint is the world's most popular presentation software which can let you create professional Cervical Cancer Introduction powerpoint presentation easily and in no time. This helps you give your presentation on Cervical Cancer Introduction in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Cervical Cancer Introduction powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

Slide 1 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10
Slide 2 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment
Slide 3 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min)
Slide 4 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210
Slide 5 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210
Slide 6 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor
Slide 7 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days)
Slide 8 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives
Slide 9 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives Primary Endpoint: to assess the relationship between 64Cu-ATSM uptake in the primary cervical tumor and progression-free survival after chemoradiotherapy. Secondary Endpoints: to assess the relationship between 64Cu-ATSM uptake and: overall survival rates of local recurrence and development of distant metastasis frequency of complete metabolic response by FDG-PET tumor volume and the frequency of lymph node metastasis at diagnosis markers of tumor hypoxia assessed by immunohistochemistry on biopsy tissue from the primary tumor ACRIN 6682 Endpoints
Slide 10 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives Primary Endpoint: to assess the relationship between 64Cu-ATSM uptake in the primary cervical tumor and progression-free survival after chemoradiotherapy. Secondary Endpoints: to assess the relationship between 64Cu-ATSM uptake and: overall survival rates of local recurrence and development of distant metastasis frequency of complete metabolic response by FDG-PET tumor volume and the frequency of lymph node metastasis at diagnosis markers of tumor hypoxia assessed by immunohistochemistry on biopsy tissue from the primary tumor ACRIN 6682 Endpoints Pre-therapy clinical whole-body FDG-PET/CT Stages IB2 –IVA invasive squamous cell carcinoma, scheduled to undergo radiation therapy and concurrent cisplatin chemotherapy Pre-therapy pelvic 64Cu-ATSM-PET/CT and analysis of tumor biopsy for hypoxic markers ACRIN 6682 Schema Concurrent chemoradiotherapy Clinical FDG-PET/CT three (3) months after completion of therapy Clinical follow-up for detection of recurrence and/or death N=100, enrollment period=18 months
Slide 11 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives Primary Endpoint: to assess the relationship between 64Cu-ATSM uptake in the primary cervical tumor and progression-free survival after chemoradiotherapy. Secondary Endpoints: to assess the relationship between 64Cu-ATSM uptake and: overall survival rates of local recurrence and development of distant metastasis frequency of complete metabolic response by FDG-PET tumor volume and the frequency of lymph node metastasis at diagnosis markers of tumor hypoxia assessed by immunohistochemistry on biopsy tissue from the primary tumor ACRIN 6682 Endpoints Pre-therapy clinical whole-body FDG-PET/CT Stages IB2 –IVA invasive squamous cell carcinoma, scheduled to undergo radiation therapy and concurrent cisplatin chemotherapy Pre-therapy pelvic 64Cu-ATSM-PET/CT and analysis of tumor biopsy for hypoxic markers ACRIN 6682 Schema Concurrent chemoradiotherapy Clinical FDG-PET/CT three (3) months after completion of therapy Clinical follow-up for detection of recurrence and/or death N=100, enrollment period=18 months Protocol Current Accrual: 7 Expecting New Sites for Accrual by late Fall 2010 Current Amendment approved by CTEP to address changes in Cu-ATSM kit formulation IND Amendment submitted August 2010 to address changes in Cu-ATSM kit formulation and compounding process Radiopharmacy Support Have continued work with radiopharmacy to support receiving the kit and compounding the dose for centers that do not have the pharmacy support to compound the dose (Readiness Oct-Nov 2010) ACRIN 6682 Status
Slide 12 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives Primary Endpoint: to assess the relationship between 64Cu-ATSM uptake in the primary cervical tumor and progression-free survival after chemoradiotherapy. Secondary Endpoints: to assess the relationship between 64Cu-ATSM uptake and: overall survival rates of local recurrence and development of distant metastasis frequency of complete metabolic response by FDG-PET tumor volume and the frequency of lymph node metastasis at diagnosis markers of tumor hypoxia assessed by immunohistochemistry on biopsy tissue from the primary tumor ACRIN 6682 Endpoints Pre-therapy clinical whole-body FDG-PET/CT Stages IB2 –IVA invasive squamous cell carcinoma, scheduled to undergo radiation therapy and concurrent cisplatin chemotherapy Pre-therapy pelvic 64Cu-ATSM-PET/CT and analysis of tumor biopsy for hypoxic markers ACRIN 6682 Schema Concurrent chemoradiotherapy Clinical FDG-PET/CT three (3) months after completion of therapy Clinical follow-up for detection of recurrence and/or death N=100, enrollment period=18 months Protocol Current Accrual: 7 Expecting New Sites for Accrual by late Fall 2010 Current Amendment approved by CTEP to address changes in Cu-ATSM kit formulation IND Amendment submitted August 2010 to address changes in Cu-ATSM kit formulation and compounding process Radiopharmacy Support Have continued work with radiopharmacy to support receiving the kit and compounding the dose for centers that do not have the pharmacy support to compound the dose (Readiness Oct-Nov 2010) ACRIN 6682 Status Site Currently Accruing: Washington University University of Iowa (pending PET Qualification) Weill Cornell (pending Cu-ATSM training) Sites Pending Participation Dependent on 3rd party Radiopharmacy Boston Medical Fox Chase MD Anderson Clinical Radiologist Able to receive Cu-ATSM in Site Pharmacy City of Hope Duke University University of Wisconsin Johns Hopkins ACRIN 6682 Status Memorial Sloan-Kettering Cancer Center Wake Forest Medical Center University of Southern California Wayne State University University of Alabama, Birmingham
Slide 13 - ACRIN 6682 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10 Background Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival Hypoxic-measuring tools are needed: To predict patient outcome To select treatments on an individual basis To evaluate early response to treatment Measurement of Hypoxia with Cu-ATSM Copper labeled dithiosemicarbazone complex (Cu-ATSM) (Fujibayashi et al.,1989, 1997; John et al., 1990; Taniuchi et al., 1995) Highly lipophilic - high membrane permeability - high extraction Reduced by bioreductive enzymes only in hypoxic cells (mitochondria in non-tumor and microsomal/cytosol in tumors) Retained in hypoxic tissues, but rapidly washes out of normoxic tissues Good hypoxic/normoxic tissue activity ratio (hypoxic/normoxic of 4.0 at 15 min) Prelimiary Data 60Cu-ATSM: Cervical Cancer 38 patients undergoing radiotherapy  chemotherapy Pre-therapy 60Cu-ATSM-PET (tumor/muscle ratio) Response to therapy assessed (follow-up 3-79 months) Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer Dehdashti et al., JNM 2008; 49:210 60Cu-ATSM: Cervical Cancer FDG 60Cu-ATSM T/M = 3.0 Responder T/M = 4.5 Non-responder Dehdashti et al., JNM 2008; 49:210 B=Bladder, P=Primary Tumor 60Cu vs. 64Cu-ATSM: Cervical Cancer Lewis, et al., JNM 2008; 49:1177 Half-life 60Cu 23.7 min 64Cu 12.7 hr Patients studied with 60Cu-ATSM-PET and 64Cu-ATSM-PET on 2 separate days (range 1 - 9 days, averaged 5.8 days) Specific Hypotheses 64Cu-ATSM-PET/CT distinguishes patients with poorer survival rate from those with better survival rate prior to initiation of therapy 64Cu-ATSM-PET/CT provides unique prognostic information different from that revealed by known prognostic factors in an invasive squamous cell cervical cancer Primary Objective To determine if higher 64Cu-ATSM uptake is associated with lower progression-free survival Study Hypotheses and Objectives Primary Endpoint: to assess the relationship between 64Cu-ATSM uptake in the primary cervical tumor and progression-free survival after chemoradiotherapy. Secondary Endpoints: to assess the relationship between 64Cu-ATSM uptake and: overall survival rates of local recurrence and development of distant metastasis frequency of complete metabolic response by FDG-PET tumor volume and the frequency of lymph node metastasis at diagnosis markers of tumor hypoxia assessed by immunohistochemistry on biopsy tissue from the primary tumor ACRIN 6682 Endpoints Pre-therapy clinical whole-body FDG-PET/CT Stages IB2 –IVA invasive squamous cell carcinoma, scheduled to undergo radiation therapy and concurrent cisplatin chemotherapy Pre-therapy pelvic 64Cu-ATSM-PET/CT and analysis of tumor biopsy for hypoxic markers ACRIN 6682 Schema Concurrent chemoradiotherapy Clinical FDG-PET/CT three (3) months after completion of therapy Clinical follow-up for detection of recurrence and/or death N=100, enrollment period=18 months Protocol Current Accrual: 7 Expecting New Sites for Accrual by late Fall 2010 Current Amendment approved by CTEP to address changes in Cu-ATSM kit formulation IND Amendment submitted August 2010 to address changes in Cu-ATSM kit formulation and compounding process Radiopharmacy Support Have continued work with radiopharmacy to support receiving the kit and compounding the dose for centers that do not have the pharmacy support to compound the dose (Readiness Oct-Nov 2010) ACRIN 6682 Status Site Currently Accruing: Washington University University of Iowa (pending PET Qualification) Weill Cornell (pending Cu-ATSM training) Sites Pending Participation Dependent on 3rd party Radiopharmacy Boston Medical Fox Chase MD Anderson Clinical Radiologist Able to receive Cu-ATSM in Site Pharmacy City of Hope Duke University University of Wisconsin Johns Hopkins ACRIN 6682 Status Memorial Sloan-Kettering Cancer Center Wake Forest Medical Center University of Southern California Wayne State University University of Alabama, Birmingham Thank You
 

Frequently Asked Questions

> About SlidesFinder?

Slidesfinder is a website that allows users to upload and share their PowerPoint presentations online. It provides a platform for individuals and businesses to share their ideas and knowledge through presentations, and for others to view and download these presentations for educational or professional purposes.
Slidesfinder offers a wide range of presentation topics and categories, including business, education, science, technology, health, and more. Users can also search for presentations using keywords, tags, or by category. The website provides tools to create professional presentations with rich media, animations, and graphics.



One of the key features of Slidesfinder is its user-friendly interface, which allows users to easily upload, view, and share presentations. Users can also embed their presentations in their websites or blogs using the website's embed code feature.
Slidesfinder also offers premium services, such as the ability to create private presentations and to download presentations in high-quality formats. However, the basic features of Slidesfinder are free to use, making it accessible to anyone who wants to share their ideas and knowledge through presentations.

> How do I register with SlidesFinder?

Go to registration page (you can see signup link on top of website page) https://www.slidesfinder.com/signup . If you have facebook/gmail account them just click on SIGN IN WITH FACEBOOK OR SIGN IN WITH GOOGLE button, by this you will be a registered member of slidesfinder without filling any form, required detail automatically will be fatch from your account. If you do not a Facebook account, then click on "Signup". Fill all required fields and you will be a registered member of slidesfinder.

> Is slidesfinder account confirmation is mandatory?

Yes it is mandetory to active your account to login.

> Do I need to signup/login on SlidesFinder before uploading a PowerPoint presentation?

Yes, you need to login with your account before uploading presentation. Your username will be displayed on your uploaded presentation. Your registered email id is needed for sending your stats of uploaded presentation.

Slidesfinder is a sharing website for PowerPoint presentations search and share. Find your interest in the form of powerpoint presentations on slidesfinder and save your valuable time . On Slidesfinder you get presentations from our huge library of professional ppt presentations. We believe in making your search INFORMATIVE and FUN. Find your best ppt presentation from a pool of PowerPoint presentations stacked under important industry categories like business & management, heath & Wellness,eduction & training etc. We provide unique informative PowerPoint presentation for marketers, presenters and educationists. These professional PowerPoint presentations are uploaded by professionals from across numerous industry segments.These ppt presentations are available for FREE download.

Not just finding your interest, but facilitate you broadcast your interest. We have created this platform for easy sharing of PowerPoint presentations, ensuring that these presentations get maximum exposure. Create your slidesfinder account and upload PowerPoint presentations for free, share on social media platforms and BUILD YOUR CROWD WITH PRESENTATION !!

The Great Buddha says, "Share your knowledge.It’s a way to achieve immortality"! So, start sharing knowledge and we are here to make that immortal !!

© 2013-2024 SlidesFinder. All rights reserved.

Re-productivity of content are not allowed. Without prior written permission from author, commercial use of any content is illegal.